Add to favorites

#Product Trends

YINGCHI M-Ultimate Boosts Depression Treatment and Research

In September 2023, YINGCHI M-Ultimate TMS received FDA approval for the treatment of major depressive disorder in adult patients, marking a significant milestone in the company's endeavor to provide safe and effective medical solutions.

Moreover, YINGCHI M-Ultimate TMS is not only limited to clinical applications; it is also playing an essential role in advancing clinical research. By partnering with leading research institutions and experts in the field, YINGCHI is committed to exploring the full potential of TMS technology in addressing a wide range of neurological and psychiatric conditions.

YINGCHI-M-Ultimate-Boosts-Depression-Treatment-and-Research

Details

  • Shenzhen, Guangdong Province, China
  • Shenzhen Yingchi Technology